{"url_path":"/sec/mcrb/8-k/2026-06-05/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-258366-index.html","accession_number":"0001193125-26-258366","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-258366-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":164,"has_tables":true,"body_markdown":"Item 9.01.\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n  \nDescription\n\n10.1\n  \n[Amendment No. 1 to Asset Purchase Agreement, dated June 2, 2026, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A.](d156701dex101.htm)\n\n10.2*\n  \n[First Amendment to Lease, dated June 4, 2026, by and between Seres Therapeutics, Inc. and 101 CPD, LLC](d156701dex102.htm)\n\n99.1\n  \n[Press Release, dated June 5, 2026](d156701dex991.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n*\n\nSchedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \nSERES THERAPEUTICS, INC.\n\nDate: June 5, 2026\n \n\n \nBy:\n \n\n/s/ Thomas J. DesRosier\n\n \n\n \nName:\n \nThomas J. DesRosier\n\n \n\n \nTitle:\n \nExecutive Vice President and Chief Legal Officer"}